CPC A61K 36/76 (2013.01) [A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/192 (2013.01); A61K 31/353 (2013.01); A61K 31/427 (2013.01); A61K 31/4965 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/675 (2013.01); A61K 31/7034 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 38/1774 (2013.01); A61K 38/21 (2013.01); A61K 39/3955 (2013.01); A61K 39/42 (2013.01); A61P 31/14 (2018.01); A61K 2236/15 (2013.01); A61K 2236/37 (2013.01); A61K 2236/39 (2013.01); A61K 2236/51 (2013.01); A61K 2236/53 (2013.01)] | 28 Claims |
1. A method of treating a condition that is a coronavirus infection in a patient, comprising orally administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition comprising a willow leaf extract, to treat the condition.
|